Talus Bio

Talus Bio is an early-stage biotechnology startup company focused on gene regulator profiling for drug development. The company spun out of University of Washington and Altius Institute for Biomedical Sciences in September 2020 and is based in Seattle, WA. Their venture-backed operations received a $4.30M grant investment on 18 August 2023 from the Andy Hill Cancer Research Endowment (CARE) Fund and the National Institutes of Health. Talus Bio's innovative platform allows for the measurement of a drug's ability to disrupt a gene regulator within its living cellular environment, providing insights into in-cell drug activity and specificity. Their approach simultaneously measures activity for approximately 1,000 gene regulators, offering comprehensive data in a single experiment. The company focuses on small-molecule drug development in oncology and aims to develop programs against previously undruggable gene regulators in cancers with poor standard of care. In addition to internal development programs, Talus Bio collaborates with pharma, biotech, and academic labs to advance their pipeline of gene regulator drugs. With a strong emphasis on data-enabled drug development, the company's platform combines innovative cell processing, high-sensitivity quantitative proteomics, and advanced downstream analytics to open up new opportunities in the field of gene regulation for drug discovery.